JP2018534245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534245A5 JP2018534245A5 JP2018513462A JP2018513462A JP2018534245A5 JP 2018534245 A5 JP2018534245 A5 JP 2018534245A5 JP 2018513462 A JP2018513462 A JP 2018513462A JP 2018513462 A JP2018513462 A JP 2018513462A JP 2018534245 A5 JP2018534245 A5 JP 2018534245A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- family
- igsf
- modified
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 29
- 230000003834 intracellular effect Effects 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 230000004957 immunoregulator effect Effects 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 230000028993 immune response Effects 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- -1 CD86 Proteins 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000011664 signaling Effects 0.000 claims 7
- 102100029740 Poliovirus receptor Human genes 0.000 claims 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 4
- 102000002698 KIR Receptors Human genes 0.000 claims 4
- 108010043610 KIR Receptors Proteins 0.000 claims 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims 4
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 210000004698 lymphocyte Anatomy 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 4
- 102100038077 CD226 antigen Human genes 0.000 claims 3
- 102100034980 ICOS ligand Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 3
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000004555 Butyrophilins Human genes 0.000 claims 2
- 108010017533 Butyrophilins Proteins 0.000 claims 2
- 102100024263 CD160 antigen Human genes 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- 101710185679 CD276 antigen Proteins 0.000 claims 2
- 108010062802 CD66 antigens Proteins 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 2
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101710093458 ICOS ligand Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
- 101150065403 NECTIN2 gene Proteins 0.000 claims 2
- 102000002356 Nectin Human genes 0.000 claims 2
- 108060005251 Nectin Proteins 0.000 claims 2
- 102100035488 Nectin-2 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 2
- 108700010039 chimeric receptor Proteins 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000001976 improved effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 108010048507 poliovirus receptor Proteins 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 102000035160 transmembrane proteins Human genes 0.000 claims 1
- 108091005703 transmembrane proteins Proteins 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218531P | 2015-09-14 | 2015-09-14 | |
| US62/218,531 | 2015-09-14 | ||
| US201662323595P | 2016-04-15 | 2016-04-15 | |
| US201662323608P | 2016-04-15 | 2016-04-15 | |
| US62/323,595 | 2016-04-15 | ||
| US62/323,608 | 2016-04-15 | ||
| US201662367822P | 2016-07-28 | 2016-07-28 | |
| US201662367819P | 2016-07-28 | 2016-07-28 | |
| US62/367,819 | 2016-07-28 | ||
| US62/367,822 | 2016-07-28 | ||
| PCT/US2016/051786 WO2017048878A1 (en) | 2015-09-14 | 2016-09-14 | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018534245A JP2018534245A (ja) | 2018-11-22 |
| JP2018534245A5 true JP2018534245A5 (https=) | 2019-10-24 |
Family
ID=57068203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513462A Pending JP2018534245A (ja) | 2015-09-14 | 2016-09-14 | 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180256644A1 (https=) |
| EP (1) | EP3350206A1 (https=) |
| JP (1) | JP2018534245A (https=) |
| KR (1) | KR20180054713A (https=) |
| CN (1) | CN108513576A (https=) |
| AU (1) | AU2016323069A1 (https=) |
| BR (1) | BR112018004965A2 (https=) |
| CA (1) | CA2997217A1 (https=) |
| EA (1) | EA201890729A1 (https=) |
| IL (1) | IL258102A (https=) |
| MX (1) | MX2018003144A (https=) |
| WO (1) | WO2017048878A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| AU2016350701B2 (en) | 2015-11-02 | 2021-08-19 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| IL262365B2 (en) * | 2016-04-15 | 2024-11-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins ICOS ligand variants and uses thereof |
| EP4706777A2 (en) | 2016-04-15 | 2026-03-11 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| CA3040296A1 (en) * | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
| EP3672990A1 (en) | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SMT202600062T1 (it) * | 2017-10-18 | 2026-03-09 | Alpine Immune Sciences Inc | Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| JP2021514379A (ja) | 2018-02-21 | 2021-06-10 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｂ７−ｈ４抗体製剤 |
| MA52416A (fr) | 2018-03-02 | 2021-04-21 | Five Prime Therapeutics Inc | Anticorps b7-h4 et leurs procédés d'utilisation |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| CN113260703A (zh) | 2018-12-24 | 2021-08-13 | 黄海东 | 突变的人2Ig-B7-H3蛋白编码基因、重组载体、包含其的宿主细胞、药物组合物及其应用 |
| US12545727B2 (en) | 2019-01-13 | 2026-02-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human Nectin-2 |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| EP3959225A4 (en) * | 2019-04-26 | 2023-07-26 | Xuanzhu Biopharmaceutical Co., Ltd. | CD80 VARIANT PROTEINS AND THEIR USES |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CN110859951A (zh) * | 2019-09-23 | 2020-03-06 | 中国药科大学 | Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用 |
| CN113087806B (zh) * | 2019-12-31 | 2022-09-06 | 华东师范大学 | 靶向多种肿瘤的新型car-t细胞及其制备和方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US7183376B2 (en) * | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| CA2411828A1 (en) * | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel co-stimulatory molecules |
| CA2682527C (en) * | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| MY180616A (en) * | 2011-06-30 | 2020-12-03 | Genzyme Corp | Inhibitors of t-cell activation |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| JP6228971B2 (ja) * | 2012-05-11 | 2017-11-08 | メディミューン，エルエルシー | Ｃｔｌａ−４バリアント |
| GB201311475D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| EP3283508B1 (en) * | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
-
2016
- 2016-09-14 JP JP2018513462A patent/JP2018534245A/ja active Pending
- 2016-09-14 BR BR112018004965A patent/BR112018004965A2/pt not_active IP Right Cessation
- 2016-09-14 US US15/759,812 patent/US20180256644A1/en not_active Abandoned
- 2016-09-14 AU AU2016323069A patent/AU2016323069A1/en not_active Abandoned
- 2016-09-14 KR KR1020187010556A patent/KR20180054713A/ko not_active Withdrawn
- 2016-09-14 EP EP16775919.0A patent/EP3350206A1/en not_active Withdrawn
- 2016-09-14 CN CN201680066217.XA patent/CN108513576A/zh active Pending
- 2016-09-14 EA EA201890729A patent/EA201890729A1/ru unknown
- 2016-09-14 MX MX2018003144A patent/MX2018003144A/es unknown
- 2016-09-14 WO PCT/US2016/051786 patent/WO2017048878A1/en not_active Ceased
- 2016-09-14 CA CA2997217A patent/CA2997217A1/en not_active Abandoned
-
2018
- 2018-03-13 IL IL258102A patent/IL258102A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534245A5 (https=) | ||
| JP2020500010A5 (https=) | ||
| TWI809130B (zh) | 嵌合跨膜蛋白及其用途 | |
| JP2018508219A5 (https=) | ||
| JP2020511136A5 (https=) | ||
| RU2018109426A (ru) | Химерные антигенные рецепторы со встроенными контролируемыми функциями | |
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| JP2020114264A5 (https=) | ||
| JP2021514631A5 (https=) | ||
| JP2019531328A5 (https=) | ||
| RU2017133637A (ru) | Иммуномодулирующие слитые белки и пути их применения | |
| JP2017501702A5 (https=) | ||
| JP2018504459A5 (https=) | ||
| RU2020135106A (ru) | Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения | |
| US20220389075A1 (en) | Engineered t cell receptors and uses thereof | |
| KR20200103703A (ko) | Nkg2d 도메인을 포함하는 다중특이적 키메라 수용체 및 이의 사용 방법 | |
| Stanietsky et al. | Paired NK cell receptors controlling NK cytotoxicity | |
| JP2020515259A5 (https=) | ||
| KR20180054713A (ko) | 조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법 | |
| NZ759969A (en) | Tagged chimeric effector molecules and receptors thereof | |
| JP2017519502A5 (https=) | ||
| JP2018525006A5 (https=) | ||
| JP2016506761A5 (https=) | ||
| JP7723420B2 (ja) | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 | |
| JP2021501587A (ja) | Ｃｄ３８指向性キメラ抗原受容体構築物 |